BOSTON--(BUSINESS WIRE)--Bionik Laboratories Corp. (“Bionik” or the “Company”), a robotics company providing neurological functional recovery solutions to stroke survivors and others with mobility challenges, offering its technology to therapists directly and services to patients in its clinical center, is proud to announce the issuance of United States Patent No. 11,744,763 by the United States Patent and Trademark Office (USPTO). This patent, titled "An Apparatus and/or Method for Positioning a Hand for Rehabilitation," marks a significant milestone in Bionik's commitment to progressing robotic technology for rehabilitation.
The newly granted patent covers groundbreaking technology developed by Bionik that is designed to enhance the rehabilitation process for individuals recovering from neurological injuries and conditions. This innovative apparatus and method provide precise positioning and guidance for patients during upper-extremity rehabilitation, offering a more effective and personalized approach to recovery. "The addition of this new patent closes out an almost 4-year patent application process," said Richard Russo, Jr., CEO of Bionik. "This patent further strengthens our intellectual property portfolio and highlights our commitment to innovation in advancing robotic technology, development, and delivery."
Bionik has a strong track record of pioneering advancements in the field of robotic assisted rehabilitation, with a focus on improving the lives of patients through innovative technology. This latest patent underscores the company's dedication to developing cutting-edge solutions that have the potential to revolutionize the rehabilitation process and improve patient outcomes.
As a leader in the industry, Bionik continues to explore new avenues for applying robotics and automation to healthcare, with a mission to provide more precise and effective rehabilitation solutions for patients worldwide.
About Bionik Laboratories Corp.
Bionik is a robotics company focused on providing neurological functional recovery solutions to stroke survivors and others with functional and mobility challenges. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products in the market and a host of other product candidates. Bionik has recently launched its Neuro-Recovery Centers of Excellence strategy, to showcase Bionik’s technology and solutions in an existing framework of revenue generating and profitable rehabilitation centers. For more information, please visit www.bioniklabs.com and connect with us on Twitter, LinkedIn, and Facebook.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," “possible,” "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology.
Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development, commercialization and distribution of robotic rehabilitation products and the roll-out of its recently-announced Neuro-Recovery Centers of Excellence strategy, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, pipeline of potential sales, capital structure or other financial items, (iii) the Company's future financial performance, including as a result of the acquisition and rebranding of the Company’s Neuro-Recovery Centers of Excellence, and the future financial performance of any such Centers of Excellence the Company may acquire or launch (iv) the market and projected market for our existing and planned products and services and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above.
Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward- looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing or increase revenue, the significant length of time and resources associated with the development and sales of our products and related insufficient cash flows and resulting illiquidity, the continued impact on the Company’s business as a result of the Covid-19 pandemic, the Company’s inability to expand the Company’s business, including its recently launched Neuro-Recovery Centers of Excellence strategy, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. The Company does not undertake to update these forward-looking statements.